USPTO Patent Application: IL-17 Antibody Compositions

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.

View original document View source feed page

What changed

This document is a publication of a United States Patent Application (US20260083842A1) filed on November 14, 2025, and published on March 26, 2026. It describes pharmaceutical products and stable liquid compositions containing IL-17 antibodies (e.g., secukinumab) and their application in treating autoimmune disorders such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. The application also covers processes for manufacturing these compositions.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future intellectual property and market exclusivity for specific therapeutic agents. Companies involved in the development or commercialization of IL-17 antibodies should be aware of this filing for competitive intelligence and patent landscape analysis.

Source document (simplified)

← USPTO Patent Applications

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

Application US20260083842A1 Kind: A1 Mar 26, 2026

Inventors

Susanne JOERG, Kathrin SERNO-SCHERSCH

Abstract

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).